oxytocin treatment
Phase 1Small molecule
oxytocin treatment is one of 11 small molecule programs targeting Tolerance. It is currently in Phase 1.
2
Indications
7
Total Trials
2
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
9 competitors in Tolerance
#DrugCompanyPhaseTrials
1Avigan
AAppili Therapeutics Inc.
Phase 2
Experimental
BiogenPreclinical
oxytocin treatment
UUniversity of Electronic Science and Technology of China
Phase 1
Levo-Dromoran
VValeant Pharmaceuticals
Preclinical
Siplizumab
UUniversity of Alabama at Birmingham
Preclinical
Tazorac
FFougera Pharmaceuticals Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Attention4 trials
The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban )
Recruiting·UUniversity of Electronic Science and Technology of China·Phase 1·NCT07140237·250 enrolled
The Effect of Oral Oxytocin and Atosiban on Social Attention
Recruiting·UUniversity of Electronic Science and Technology of China·Phase 1·NCT07093060·250 enrolled
Show 1 more trial
Oxytocin2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for oxytocin treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details